AAV Assembly via Host Cell Protein Modulation for Higher rAAV Titer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant adeno-associated viruses (rAAV) in mammalian cell lines yield low particle numbers, necessitating improved production techniques for clinical and laboratory applications.
Innovation Solution
Modulating genes and proteins in cultured cells, such as Hsc/Hsp70, vacuolar-specific H+ ATPase, and cyclin-dependent kinase 2, through knockout, knockdown, overexpression, or chemical compounds to enhance rAAV production and assembly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional mammalian cell culture systems are used for rAAV production, then the production process is simple and well-established, but the number of rAAV particles generated per cell is low (on the order of 10E4 particles)
Solution Approach 1:
The patent applies parameter changes by modulating the expression levels of specific host cell proteins (Hsc/Hsp70, vacuolar-specific H+ ATPase, cyclin-dependent kinase 2) to optimize rAAV assembly conditions. By increasing or decreasing the activity of these proteins, the patent transforms the cellular environment to enhance rAAV production titer from 10E4 to potentially 10E6 particles per cell, resolving the contradiction between simple production methods and low productivity.
Solution Approach 2:
The patent introduces intermediary proteins (Hsc/Hsp70 chaperone system, vacuolar-specific H+ ATPase, cyclin-dependent kinase 2) that mediate the assembly process. These intermediaries facilitate capsid formation and maturation by assisting in protein folding, membrane trafficking, and cell cycle regulation, thereby enhancing rAAV production without requiring complete redesign of the production system.
2Productivity
If gene modulation methods (knockout, knockdown, overexpression) are applied to improve rAAV assembly, then production titer increases, but the process complexity and time required for optimization increase
Solution Approach 1:
The patent employs preliminary action by pre-identifying and characterizing the specific host cell proteins (Hsc/Hsp70, vacuolar-specific H+ ATPase, cyclin-dependent kinase 2) that are critical for rAAV assembly. By conducting prior research to determine which proteins to modulate and in what direction, the patent eliminates the need for time-consuming trial-and-error optimization during actual production, thus reducing loss of time while maintaining high productivity.
3Productivity
If chemical compounds are added to culture media to modulate gene activity, then rAAV production is enhanced, but the cost of production and complexity of process control increase
Solution Approach 1:
The patent utilizes small molecule chemical compounds that can be added to culture media to temporarily modulate protein activity during the rAAV production process. These disposable chemical modulators provide transient enhancement of assembly efficiency without requiring permanent genetic modification or complex equipment changes, thereby increasing productivity while keeping process control complexity manageable.
Data Source
AI summary
Described herein are methods and compositions for modifying cells to improve the assembly of adeno-associated viruses (AAVs).